Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Solid Q3 performance across our value drivers Growth1 Q3 Group sales +5%; 9M +4% Q3 IM sales +7%; 9M +6% Q3 Sandoz sales -2%; 9M -4% 1 Innovation 177 Lu-PSMA-617 mCRPC post-taxane submission (US) KymriahⓇ r/r FL submission (US, EU) Remibrutinib CSU Ph2b showed rapid, effective disease control CosentyxⓇ GCA Ph2 TitAIN positive readout Canakinumab NSCLC 1L, CANOPY1 Ph3 readout 3 Iptacopan C3G Ph2 final readout (3mo), IgAN addtl analyses (6mo) positive Productivity1 2 ESG Q3 Group core operating income +9%; 9M +4% Positive Ph2b for next generation antimalarial therapy Q3 IM core operating income +13%; 9M +8% Q3 IM core margin 37.8% (+1.9%pts cc); 9M 37.1% Commitment to net zero (2040) with Science-Based Targets Reached ~29m patients in LMICs to date in 2021 through our flagship program and strategic innovative brands All growth % in cc IM - Innovative Medicines division BTD Breakthrough Therapy designation 1. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 6 Investor Relations | Q3 2021 Results 4 ✓ NOVARTIS | Reimagining Medicine

View entire presentation